Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07217795

Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building

Developing a Telehealth Intervention for Alcohol and Trauma Among LGBTQ+ People

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
University of Rhode Island · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a two-part study to develop and test a brief, virtual therapy program for lesbian, gay, bisexual, transgender, and queer (LGBTQ+) people who have experienced trauma and use alcohol. Phase 1: You'll be invited to share your perspective to help make the program relevant, inclusive, and affirming. Phase 2: You may have the opportunity to try the adapted program by receiving free virtual therapy with LGBTQ+-affirming therapists.

Conditions

Interventions

TypeNameDescription
BEHAVIORALCBT + expressive writingThis study will test a remotely delivered intervention combining Cognitive Behavioral Therapy (CBT) and Expressive Writing (EW) to address unhealthy alcohol use and traumatic stress among sexual minority women (SMW; e.g., lesbian, bisexual women) and transgender and gender-diverse (TGD) individuals. The intervention, called Recovery through Inhibitory Learning, Self-Efficacy Building, Problem-Solving, and Community Building (RISE), integrates CBT modules on assertiveness, problem-solving in high-risk situations, and building social connections with a brief EW program tailored to SMW and TGD participants. Four modules from the Unified Protocol (UP), a transdiagnostic CBT approach, will be adapted: (1) psychoeducation, goal setting, and motivational enhancement; (2) mindful emotional awareness; (3) cognitive flexibility; and (4) countering emotion-driven behaviors.
BEHAVIORALWait-List ControlParticipants assigned to the wait-list will not receive active treatment during the study period but will be offered the RISE intervention afterward.

Timeline

Start date
2025-11-30
Primary completion
2026-11-01
Completion
2028-09-01
First posted
2025-10-16
Last updated
2025-12-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07217795. Inclusion in this directory is not an endorsement.